BioSpace News Archive

Covalon Technologies Ltd. (TSXV: COV) (OTCQX: CVALF), an advanced medical technologies company, will release its Q2 Fiscal 2021 financial results on Monday, May 31 st , 2021 before markets open. A conference call to discuss the financial results will be held on Monday, May 31 st , 2021

Selexis SA, a JSR Life Sciences company, announced that Great Place to Work® has designated the Company among the “Best Workplaces™ Switzerland” in 2021.

DexCom, Inc. announced that management will present an update on Dexcom at the following upcoming investor conference

SANUWAVE Health, Inc., a leading provider of next-generation advanced wound care medical systems for the repair and regeneration of skin and vascular structures and the research for new applications for focused, shockwave systems in the non-medical field presented results from a clinical case series that demonstrated improved wound healing when treated with its FDA-cleared, non-invasive pulsed acoustic cellular expression system dermaPACE® System.

Individuals with genetic high cholesterol, heart disease or both, who were infected with COVID-19 had more heart attacks according to new research by the FH Foundation.

Aptevo Therapeutics Inc., a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIRTM and ADAPTIR-FLEXTM platform technologies announced that the company has initiated the expansion phase of lead anti-leukemia drug candidate, APVO436, in adult patients with acute myeloid leukemia with a multi-center, multi-arm trial using the active recommended dose identified in the dose escalation phase of the study.

Meridian Bioscience, Inc. (NASDAQ: VIVO) announced today participation in two upcoming investor conferences. Jack Kenny, Chief Executive Officer, will participate in a live, virtual fireside chat at the 41st Annual William Blair Growth Stock Conference on Wednesday, June 2, 2021 at 4:20 PM ET.

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it will participate in a fireside chat and host meetings with investors at the upcoming Jefferies Virtual Healthcare Conference.

New funding awards include up to $2.6M to Eloxx Pharmaceuticals to identify potential therapies for CF nonsense mutations

AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has entered into a two-year extension of its Material Transfer and Research Agreement with Shenzhen Smoore Technology Limited (Smoore), a subsidiary of Smoore International Holdings Limited (HKEX: 6969), with the goal of developing Ampligen as a potential inhalation therapy for COVID-19 and potentially other respiratory viral diseases.